🔗 Share this article

While the US continues making unprecedented changes to its vaccine recommendations, an unexpected name appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by questioning Covid vaccinations throughout the global health crisis and has concentrated on potential fatalities after Covid immunization in her short position at the Food and Drug Administration.

Planned Changes to Pediatric Vaccine Schedule

Agency leaders were set to reveal major revisions to the pediatric vaccine schedule recently, bringing the US with the Danish vaccine program, sources say – a major change that would place the US at odds with many the international standard with no evidence for improved outcomes. The planned update has been pushed back until the coming year.

In place of the top vaccines chief, Dr. Høeg is scheduled to speak at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

A Shift at the FDA

This interim role could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting certain pediatric vaccine recommendations in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a citizenry approximately the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Background

Dr. Høeg has little discernible track record in pharmaceutical research, approval processes or leadership, which has been typical for previous heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a major agency. She is not an expert in industry regulation.”

Previous directors of CBER would “be deeply familiar with laws and regulations and the research of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the kind of background that previous people who ran CBER have had.”

This division has an vast range of responsibilities at the FDA, Woodcock stated.

“The public just focuses on the novel medication approvals, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these need to be managed,” Dr. Woodcock said. “The area you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial leadership aspect to the job, which manages over 5,000 employees. “It is a huge leadership role, if you execute it properly,” she said.

Official Statement and Disputed Programs

When asked about questions about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among agency officials on immunizations, a representative said that the “questions are based on inaccurate assumptions”.

“Her experience aligns with the responsibilities of her role,” the spokesperson said, citing the period Høeg spent advising the agency head on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's controversial priority voucher program, a disputed rapid medication authorization process that reportedly concerned her preceding directors. “By what process are these drugs being chosen for this fast-track system? Who is making the decisions?” Howard questioned. “There’s a lot of secrecy going on at the agency right now.”

Overall, he stated, “the agency appears to be shifting towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Public Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, history, some experts observe. She authored a research paper using non-validated public submissions to assess the incidence of heart inflammation after COVID-19 immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the new government included altering guidelines for recently developed shots and ending “unnecessary” immunizations, she remarked after the election on a online show. At the FDA, Høeg has according to sources proposed barring teenage boys from getting COVID-19 vaccines.

“She is an complete dogmatist who starts off with her preconceived notions and tailors the evidence to retrofit the data in a very deceptive, untruthful way,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|